(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2013 (21.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/173417 A2

(51) International Patent Classification:
A61K 38/26 (2006.01) *A61P 3/10* (2006.01)
A61K 45/06 (2006.01) *A61P 9/10* (2006.01)
A61K 31/426 (2006.01) *A61P 9/12* (2006.01)
A61K 31/4985 (2006.01) *A61P 3/04* (2006.01)
A61P 3/06 (2006.01)

(21) International Application Number:
PCT/US2013/041076

(22) International Filing Date:
15 May 2013 (15.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/648,110 17 May 2012 (17.05.2012) US

(71) Applicant: **TRANSTECH PHARMA, INC.** [US/US]; 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(72) Inventors: **VALCARCE LOPEZ, Maria Carmen**; 1785 Deer Run Court, Oak Ridge, North Carolina 27310 (US). **FONG, Tung**; 23 Smithwold Road, Somerset, New Jersey 08873 (US).

(74) Agent: **ROLLINS, Samuel B.**; TransTech Pharma, Inc., 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE TREATMENT OF DIABETES

(57) Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-yl-sulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.




FIGURE 6

WO 2013/173417 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*